MedNous | Business of medical innovation

Evernow Publishing Ltd Privacy Policy. Read more.

Free featured article

LifeArc provides seed funding to Ducentis

Country

United Kingdom

The UK medical charity LifeArc has provided £1.5 million in seed funding to a four-year old company, Ducentis BioTherapeutics Ltd, that is investigating molecules for treating inflammation and autoimmune disease. Ducentis was co-founded in 2015 by Philip Huxley, an expert in drug discovery, and David Blackbourn, head of the School of Biosciences and Medicine at the University of Surrey, UK to exploit the CD200 axis.

Jean-Paul Kress appointed CEO at MorphoSys

Country

Germany

Jean-Paul Kress, formerly of Biogen Inc and Sanofi Genzyme, is to take over as chief executive of MorphoSys AG on 1 September, succeeding Simon Moroney, the company’s co-founder and CEO. Dr Kress will assume the leadership position just as MorphoSys seeks to register and commercialise its first wholly-owned product tafasitamab for diffuse large B cell lymphoma.

NOXXON to test oligonucleotide in new indication

Country

Germany

NOXXON Pharma NV is to test its RNA oligonucleotide drug NOX-A12 in a new cancer indication after signing an agreement with an unidentified large pharma company to conduct preclinical studies of the drug.